REGEMAT 3D Secures Patent for Revolutionary BMAP® KNEEBioreactor

Granada, Spain – May 5, 2024 – REGEMAT 3D, an innovative biomedical company specialized in
the design and development of personalized 3D bioprinted solutions, is proud to say that its innovative
BMAP® KNEE Bioreactor has now been patented. This achievement attains relevance for
regenerative medicine and orthopedic research.
The BMAP® KNEE is the first and only commercially available bioreactor system in the world for the
production of fully functional cartilage. This novel bioreactor system has been specifically designed to
model the anatomy and physiology of the human knee joint, providing a physiologically relevant
microenvironment for the maturation of patient-specific, 3D bioprinted cartilage substitutes.
This technology represents a quantum leap in developing solutions for sophisticated biofabrication,
thus opening hitherto unexplored avenues toward the management of cartilage injury and disease.
BMAP® KNEE will be a game-changing pillar that is going to transform joint repair as performed by
the discipline of regenerative medicine, offering hope to millions of orthopedic patients around the
world.
This development is in line with the mission of REGEMAT 3D-to provide state-of-the-art technologies
that enable breakthroughs in tissue engineering and personalized medicine.
For further information about the BMAP® KNEE Bioreactor and its range of applications, please
contact info@regemat3d.com.